TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05148715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
Study: NCT05413902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine Injectable Solution
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT04892342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Administered via intravenous (IV) infusion
Study: NCT05203588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml Injectable Solution [Prolia]
Description: Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: calcium and vitamin D
Description: calcium (≥1·0 g) and vitamin D (≥400 IU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium and vitamin D
Description: calcium (≥1·0 g) and vitamin D (≥400 IU).
Study: NCT06669260

Intervention type: PROCEDURE
Intervention: TEThA technique
Description: Patient in an orthostatic position, previously marked varicose veins will be punctured with a tracing adjacent to them, surrounding their edges. Applying an augmented reality device and Doppler ultrasound (Doppler USG), the marking will be complemented in the supine position. These punctures will in turn be carried out using the TEThA technique - endovenous thermoablation of tributary veins by means of transfixation - and will be done sequentially as they are treated one by one with endo- and perivenous thermoablation under generous tumescence with 0.08% lidocaine in saline solution. The laser used to treat the tributary veins will also be 1470 nm and will be fired as the fiber is removed at a speed of 1 mm/sec and power ranging from 5 to 7 watts.
Study: NCT06670092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta Therapy
Description: The intervention is carried out using Vojta therapy for one month, with one session per day, 5 days a week. This therapy is carried out by an expert physiotherapist. Vojta therapy is a non-experimental, painless, non-invasive therapy with no adverse effects, which is based on triggering repeated motor reactions or innate movement patterns (reflex locomotion patterns) in the trunk and limbs based on defined stimuli and starting from specific postures.~Both groups will undertake a pre-treatment assessment, a post-treatment assessment at the end of the one-month intervention period, and a final follow-up assessment one month after the end of the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervetion
Description: No intervetion group
Study: NCT04864808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
Study: NCT06008977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Test
Description: Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Test
Description: Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
Study: NCT04637685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centurion Phacoemulsification System
Description: Infusion Pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centurion Phacoemulsification System
Description: Infusion Pressure
Study: NCT05200806

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Narcotic ERAS Post-Operative Pain Management
Description: As described previously.
Study: NCT06237699

Intervention type: OTHER
Intervention: Digital ICU diary
Description: A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).

Intervention type: OTHER
Intervention: Digital ICU diary
Description: A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).
Study: NCT04835415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral retrolaminar block
Description: in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
Study: NCT05107154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioural Therapy
Description: DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
Study: NCT06078995

Intervention type: DRUG
Intervention: Tenecteplase
Description: Thrombolysis wtih rhTNK-tPA

Intervention type: DRUG
Intervention: Alteplase
Description: Thrombolysis wtih rt-PA
Study: NCT04552080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
Study: NCT06241651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: Firstly, we will attempt LBBP if the patient is allocated to the experimental group. If we can not achieve LBBP successfully, then we will turn to attempt HBP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Implantation of RA lead, RV lead and LV lead are attempted using the standard-of-care technique.
Study: NCT06030479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical adrenaline
Description: Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warm saline
Description: Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees).
Study: NCT05282355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Our aim was to examine the impact astaxanthin would have, if any, on markers of metabolic flexibility in overweight individuals in comparison to a placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To have adequately test the effects of astaxanthin, we provided one group a placebo matched in appearance and taste.
Study: NCT04934111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP-nCOV saRNA-02 Vaccine
Description: a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
Study: NCT05815186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
Study: NCT06533618

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system
Description: All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system
Description: All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system
Description: All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system
Description: All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
Study: NCT04968067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App group
Description: In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nursing telephone advice (NTA) group
Description: All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
Study: NCT06701019

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview/focus group discussion
Description: All participants will be asked via email for their medical history/status and demographic information.~Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option.
Study: NCT06247254

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive Clinic Management
Description: The ICM arm includes BP management at in-person follow-up visits occurring every 2 months when BPs are at target and if not in target, monthly visits. Medications will be adjusted to lower BP to the target using evidence-based guidelines and in the context of whether the participant can effectively manage their medications and BP. ICM participants will receive a COMPASS Care plan, which will evaluate social and functional factors for managing stroke recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Tailored Telehealth Management
Description: The ITTM intervention involves a comprehensive, multi-dimensional approach to using real-time BP data to manage BP after stroke. ITTM includes an in-person visit during which participants will complete a series of questionnaires within the COMPASS-CP® web application and will receive a COMPASS-BP Action Plan home safety checklist, BP Matters documents, and referrals to local resources, as needed.
Study: NCT06383143

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06567288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spencer mscle energy technique
Description: The effectiveness of MET found in chronic capsulitis is due to its effect on relieving pain, ensuring ROM incretions, and developing functional activities due to the muscle contraction in a precise direction and in a monitored position over resistance to assist in improving joint range by advancing joint flexibility. This procedure is suggested for all joints with limited ROM (Butt \& Tanveer, 2022).
Study: NCT05074602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8008
Description: Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
Study: NCT05969028

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: igel
Description: First responder ventilation strategy. First responders in King County routinely use the BVM as part of core treatment of SCA. As part of EMS training, we have introduced a training module for use of the igel in simulated resuscitation, which has been enthusiastically accepted by EMS leadership and providers. The i-gel is already successfully practiced by BLS providers in a number of other communities and challenges in training and clinical application will be monitored, but not anticipated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Rate
Description: Compression rates. The EMS system routinely measures EMS CPR performance and specifically the chest compression rate using information derived and electronically recorded from defibrillator patches. As detailed in the Background section, this CPR surveillance activity highlights the variability of compression rates across the guideline-directed range of 100-120 compressions per minute. In addition our CPR surveillance indicates that a metronome can be used to obtain and maintain a specific compression rate within the parameters specified by this trial. This will be the tool used to guide compliance with the assigned chest compression rate by on-scene providers.
Study: NCT05643131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyivy Intravaginal Device
Description: Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
Study: NCT05620459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge augmentation using chin bone ring with simultaneous implant placement
Description: surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
Study: NCT05764200

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Two day supplementation of a complex fiber mixture
Description: Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Two day supplementation of a complex fiber mixture
Description: Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
Study: NCT06568120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dragon themed nebulizer masks
Description: This study is an experimental investigation aiming to evaluate the effect of a dragon-themed nebulizer mask (Figure 1), identified during a literature review by the researchers, on the duration of inhaler treatment application, treatment adherence, and children's fear levels. The dragon-designed nebulizer mask, with its colorful and toy-like appearance, is intended to calm children using pediatric aerosol masks. The mask is made of very soft, latex-free plastic, ensuring comfortable use for pediatric patients. It is compatible with all nebulizers and suitable for use in hospital settings. Unlike standard nebulizer masks, its appearance is designed with a dragon character specifically for pediatric patients. The mask is manufactured in China.
Study: NCT06529458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1 Group
Description: The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 2 Group
Description: The researcher will apply drops of ginger oil to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy, using circular motions. At the same time, the researcher will have the patient or a relative repeat the method and apply it at home three times a day before meals for 5 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No interference will be made